Muscarinic acetylcholine receptor-interacting proteins (mAChRIPs): targeting the receptorsome (original) (raw)
Related papers
Muscarinic acetylcholine receptors: novel opportunities for drug development
Nature Reviews Drug Discovery, 2014
The muscarinic acetylcholine receptors (mAChRs) comprise a family of five related G protein-coupled receptors (GPCRs) belonging to the α-branch of class A GPCRs 1 . The mAChR family consists of five distinct subtypes, denoted M 1 to M 5 (and encoded by the genes CHRM1 to CHRM5). Three of these receptor subtypes (M 1 , M 3 and M 5 ) have been shown to couple to G proteins of the G q/11 family, whereas the remaining two subtypes (M 2 and M 4 ) preferentially signal through the G i/o family of G proteins 2 . The mAChRs have a central role in human physiology, regulating heart rate, smooth muscle contraction, glandular secretion and many fundamental functions of the central nervous system (CNS) 3 .
Functional and biochemical basis for multiple muscarinic acetylcholine receptors
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1985
The novel antimuscarinic compound pirenzepine (PZ) has generated considerable interest in the basis and the implications of muscarinic acetylcholine receptor (mAChR) heterogeneity. [3H]PZ has been used extensively to identify and characterize the putative M1 (high affinity for PZ) mAChR subtype, which predominates in central nervous system (CNS) and ganglia. The heterogeneity sensed by PZ is not identical to the heterogeneity sensed by agonists. Differences in effector coupling do not necessarily provide a simple explanation for the molecular basis of these putative M1 and M2 subtypes. Therapeutic and untoward effects of muscarinic drugs may be mediated by independent mAChR subpopulations which may be pharmacologically exploited to produce more highly selective as well as efficacious new drugs.
Muscarinic receptor family interacting proteins: role in receptor function
Journal of neuroscience methods, 2011
a b s t r a c t G protein-coupled receptors constitute one of the most important families of membrane receptors through which cells respond to extracellular stimuli. Receptors of this superfamily likely function as signal transduction complexes. The identification and analysis of their components provide new insights into a better understanding of these receptors' function and regulation. We used tandem-affinity purification and mass spectrometry as a systematic approach to characterize multiprotein complexes in the acetylcholine muscarinic receptor subfamily. To overcome the limitations associated with membrane protein receptor solubilization with detergents, we developed a strategy in which receptors are co-expressed with a cytoplasmic minigene construct, encoding the third intracellular loop and the C-terminal tail tagged to the tandem-affinity-cassette of each receptor subtype. Numerous protein complexes were identified, including many new interactions in various signalling pathways. Systematic identification data set together with protein interactions reported in the literature revealed a high degree of connectivity. These allow the proposal, for the first time, of an outline of the muscarinic interactome as a network of protein complexes and a context for a more reasoned and informed approach to drug discovery and muscarinic receptor subtype specificities.
Regulation of muscarinic acetylcholine receptor signaling
Pharmacology & Therapeutics, 2003
Multiple mechanisms regulate the signaling of the five members of the family of the guanine nucleotide binding protein (G protein)coupled muscarinic acetylcholine (ACh) receptors (mAChRs). Following activation by classical or allosteric agonists, mAChRs can be phosphorylated by a variety of receptor kinases and second messenger-regulated kinases. The phosphorylated mAChR subtypes can interact with b-arrestin and presumably other adaptor proteins as well. As a result, the various mAChR signaling pathways may be differentially altered, leading to short-term or long-term desensitization of a particular signaling pathway, receptor-mediated activation of the mitogenactivated protein kinase pathway downstream of mAChR phosphorylation, as well as long-term potentiation of mAChR-mediated phospholipase C stimulation. Agonist activation of mAChRs may also induce receptor internalization and down-regulation, which proceed in a highly regulated manner, depending on receptor subtype and cell type. In this review, our current understanding of the complex regulatory processes that underlie signaling of mAChR is summarized. D
Neurochemical research, 2003
In this review we report recent findings on the physiological role of the five known muscarinic acetylcholine receptors (mAChRs) as shown by gene targeting technology. Using knockout mice for each mAChRs subtype, the role of mAChRs subtypes in a number of physiological functions was confirmed and new activities were discovered. The M1 mAChRs modulate neurotransmitter signaling in cortex and hippocampus. The M3 mAChRs are involved in exocrine gland secretion, smooth muscle contractility, pupil dilation, food intake, and weight gain. The role of the M5 mAChRs involves modulation of central dopamine function and the tone of cerebral blood vessels. mAChRs of the M2 subtype mediate muscarinic agonist-induced bradycardia, tremor, hypothermia, and autoinhibition of release in several brain regions. M4 mAChRs modulate dopamine activity in motor tracts and act as inhibitory autoreceptors in striatum. Thus, as elucidated by gene targeting technology, mAChRs have widespread and manifold functi...
IUPHAR/BPS Guide to Pharmacology CITE, 2019
Muscarinic acetylcholine receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Muscarinic Acetylcholine Receptors [45]) are GPCRs of the Class A, rhodopsin-like family where the endogenous agonist is acetylcholine. In addition to the agents listed in the table, AC-42, its structural analogues AC-260584 and 77-LH-28-1, N-desmethylclozapine, TBPB and LuAE51090 have been described as functionally selective agonists of the M1 receptor subtype via binding in a mode distinct from that utilized by non-selective agonists [243, 242, 253, 155, 154, 181, 137, 11, 230]. There are two pharmacologically characterised allosteric sites on muscarinic receptors, one defined by it binding gallamine, strychnine and brucine, and the other defined by the binding of KT 5720, WIN 62,577, WIN 51,708 and staurosporine [161, 162].
FEBS Letters, 1993
CHO cells express both of the phosphoinositidase C-linked G-proteins G, and G,, G,,a is some 2.5-fold more highly expressed than G,a in membranes of these cells. Following transfection and stable expression of CHO cells wtth DNA encoding the human muscarimc Ml acetylcholine (HMl) receptor, chronic treatment of the cells with the cholinergic agonist carbachol resulted in down-regulation of membrane levels of both G,a and G,I,. Dose-response curves to carbachol produced identical EC,, values for agonist-Induced down-regulation of the two G-proteins and both were down-regulated with the same time course. These data indicate that the HMl receptor interacts with and activates both G,a and G,,a equivalently and non-selectively in a whole cell system m which the receptor has access to both G-proteins. Guanine nucleotide bmdmg protein; Phosphohpase C: Inosttol trisphosphate; Muscarinic acetylcholine receptor Correspondence address. G. Milligan,
Pharmacological approaches to targeting muscarinic acetylcholine receptors
Recent patents on CNS drug discovery, 2014
The presence of cholinergic system markers and muscarinic receptor subtypes in several tissues also of nonneuronal type has been largely demonstrated. Acetylcholine, synthesized in the nervous system, can locally contribute to modulate cell proliferation, survival and apoptosis. Considering that the cholinergic system functions are impaired in a number of disorders, the identification of new drugs regulating these functions appears of great clinical relevance. The possible involvement of muscarinic acetylcholine receptors in different pathologies has been proposed in recent years and is becoming an important area of study. However, the lack of selective muscarinic receptor ligands has for long time limited the therapeutic treatment based on muscarinic receptors as targets. To date, some muscarinic ligands such as xanomeline (patent, US5980933) or cevimeline (patents US4855290, US5571918) have been developed for the treatment of several pathologies (Alzheimer's and Sjogren's ...
Structure and activation of muscarinic acetylcholine receptors
Biochemical Society Transactions, 2003
A homology model of the M1 muscarinic acetylcholine receptor, based on the X-ray structure of bovine rhodopsin, has been used to interpret the results of scanning and point mutagenesis studies on the receptor's transmembrane (TM) domain. Potential intramolecular interactions that are important for the stability of the protein fold have been identified. The residues contributing to the binding site for the antagonist, N-methyl scopolamine, and the agonist, acetylcholine, have been mapped. The positively charged headgroups of these ligands probably bind in a charge-stabilized aromatic cage formed by amino acid side chains in TM helices TM3, TM6 and TM7, while residues in TM4 may participate as part of a peripheral docking site. Closure of the cage around the headgroup of acetylcholine may be part of the mechanism for transducing binding energy into receptor activation, probably by disrupting a set of Van der Waals interactions between residues lying beneath the binding site that h...